Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase

3 Aug 2022

Abstract excerpt

The Apicomplexa comprise a large phylum of single-celled, obligate intracellular protozoa that include Toxoplasma gondii , Plasmodium , and Cryptosporidium spp., which infect humans and animals and cause severe parasitic diseases. Available therapeutics against these diseases are limited by suboptimal efficacy and frequent side effects, as well as the emergence and spread of resistance. We use a drug repurposing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Toxoplasma gondii Research Studies
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35921477
DOI: 10.1126/scitranslmed.abn3231

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinasePMID 35921477Read ↗

A drug repurposing screen identifies altiratinib as a selective inhibitor of a key regulatory splicing kinase and a potential therapeutic for toxoplasmosis and malariaSemantic proximity Read ↗

Inhibition of <i>Pf</i> CLK3 a master regulator of malaria parasite RNA-splicing provides the basis for a radical cure for malariaSemantic proximity Read ↗

Targeting Protein Kinases in the Malaria Parasite: Update of an Antimalarial Drug TargetSemantic proximity Read ↗

Bumped Kinase Inhibitors Inhibit both Toxoplasma gondii MAPKL1 and CDPK1Semantic proximity Read ↗

Transcriptional Responses to Bumped Kinase Inhibitor BKI-1708 in <em>Toxoplasma gondii</em> and Human FibroblastsSemantic proximity Read ↗

Inhibiting parasite proliferation using a rationally designed anti‐tubulin agentSemantic proximity Read ↗

Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondiiSemantic proximity Read ↗

An overview of cdc2‐like kinase 1 (Clk1) inhibitors and their therapeutic indicationsSemantic proximity Read ↗

Antimalarial drug discovery: targeting protein kinasesSemantic proximity Read ↗

The critical role of mode of action studies in kinetoplastid drug discoverySemantic proximity Read ↗

New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infectionsSemantic proximity Read ↗

Plasmodial Kinase Inhibitors: License to Cure?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.